Literature DB >> 8549025

Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia.

H J Lemmens1.   

Abstract

The pure mu-receptor opioid agonists fentanyl, sufentanil and alfentanil are commonly used to provide the specific anti-nociceptive component of a balanced anaesthesia technique. Trefentanil and remifentanil are new opioids with a very short duration of action. Remifentanil has an ester structure and is very rapidly metabolised by blood and tissue esterases. Different perioperative stimuli require different plasma concentrations to suppress responses of the patient. The ability of the anaesthesiologist to select a precise dosage scheme for the individual patient is impeded by the large interindividual pharmacokinetic and pharmacodynamic variability. In addition, the combination of opioids and other drugs used to produce the desired components of balanced anaesthesia may exert additive, synergistic or antagonistic effects. Knowledge of factors influencing the pharmacokinetics and pharmacodynamics is still fragmentary and often controversial. Consequently, the opioid dose needs to be adjusted according to the responses of the patient during surgery to ensure adequate anaesthesia and rapid recovery. The duration of action is not predicted by the elimination half-life alone. The decline in effect-site concentration is dependent on the complex entity of infusion duration, and pharmacokinetic and pharmacodynamic parameters. Computer simulations of infusions of varying duration have been extremely useful when selecting an opioid for a specific clinical scenario on a rational basis. Traditionally, opioids are still administered by intermittent bolus injections. A disadvantage of this method of administration is that plasma concentrations fluctuate above and below the level required for adequate anaesthesia. Computer-assisted infusion pumps make it possible to target a particular drug concentration in plasma and to maintain or change this concentration as needed. This technique provides more stable anaesthesia and a more rapid recovery of the patient.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8549025     DOI: 10.2165/00003088-199529040-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  66 in total

1.  Triple anesthetic combination: propofol-midazolam-alfentanil.

Authors:  H R Vinik; E L Bradley; I Kissin
Journal:  Anesth Analg       Date:  1994-02       Impact factor: 5.108

2.  Pharmacokinetic parameters relevant to recovery from opioids.

Authors:  E J Youngs; S L Shafer
Journal:  Anesthesiology       Date:  1994-10       Impact factor: 7.892

3.  The pharmacokinetics of sufentanil in surgical patients.

Authors:  J G Bovill; P S Sebel; C L Blackburn; V Oei-Lim; J J Heykants
Journal:  Anesthesiology       Date:  1984-11       Impact factor: 7.892

4.  Vomiting after alfentanil anesthesia: effect of dosing method.

Authors:  G S Okum; P Colonna-Romano; J C Horrow
Journal:  Anesth Analg       Date:  1992-10       Impact factor: 5.108

5.  Fentanyl and sufentanil increase intracranial pressure in head trauma patients.

Authors:  R J Sperry; P L Bailey; M V Reichman; J C Peterson; P B Petersen; N L Pace
Journal:  Anesthesiology       Date:  1992-09       Impact factor: 7.892

6.  Fentanyl or alfentanil decreases the minimum alveolar anesthetic concentration of isoflurane in surgical patients.

Authors:  C L Westmoreland; P S Sebel; A Gropper
Journal:  Anesth Analg       Date:  1994-01       Impact factor: 5.108

7.  Potentiation of acute opioid-induced respiratory depression and reversal of tolerance by the calcium antagonist nimodipine in awake rats.

Authors:  F Ruiz; M Dierssen; J Flórez; M A Hurlé
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

8.  Sufentanil pharmacokinetics in patients with cirrhosis.

Authors:  M Chauvin; C Ferrier; J P Haberer; C Spielvogel; C Lebrault; J C Levron; P Duvaldestin
Journal:  Anesth Analg       Date:  1989-01       Impact factor: 5.108

9.  EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil.

Authors:  J C Scott; K V Ponganis; D R Stanski
Journal:  Anesthesiology       Date:  1985-03       Impact factor: 7.892

10.  Pharmacokinetics of sufentanil in obese patients.

Authors:  A E Schwartz; R S Matteo; E Ornstein; W L Young; K J Myers
Journal:  Anesth Analg       Date:  1991-12       Impact factor: 5.108

View more
  6 in total

Review 1.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Pharmacokinetics of opioids in renal dysfunction.

Authors:  G Davies; C Kingswood; M Street
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.

Authors:  J Scholz; M Steinfath; M Schulz
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

4.  Design, synthesis, and biological evaluation of C6-difluoromethylenated epoxymorphinan Mu opioid receptor antagonists.

Authors:  Andrew J Kassick; Anny Treat; Nestor Tomycz; Michael G Feasel; Benedict J Kolber; Saadyah Averick
Journal:  RSC Med Chem       Date:  2021-11-02

5.  Synthesis and biological evaluation of some novel 1-substituted fentanyl analogs in Swiss albino mice.

Authors:  Shiv Kumar Yadav; Chandra Kant Maurya; Pradeep Kumar Gupta; Ajai Kumar Jain; Kumaran Ganesan; Rahul Bhattacharya
Journal:  Interdiscip Toxicol       Date:  2014-11-15

Review 6.  Novel Synthetic Opioids: The Pathologist's Point of View.

Authors:  Paolo Frisoni; Erica Bacchio; Sabrine Bilel; Anna Talarico; Rosa Maria Gaudio; Mario Barbieri; Margherita Neri; Matteo Marti
Journal:  Brain Sci       Date:  2018-09-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.